Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2056 to 2070 of 8930 results

  1. Bipolar disorder: assessment and management (extraordinary review)

    In development Reference number: GID-NG10380 Expected publication date: TBC

    NICE guideline
    In development

  2. V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]

    Awaiting development Reference number: GID-TA11881 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]

    Awaiting development Reference number: GID-TA11199 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. NY-ESO-1 T-cells for treating synovial sarcoma [ID1286]

    In development Reference number: GID-TA10205 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519]

    In development Reference number: GID-TA11649 Expected publication date:  14 October 2026

    Technology appraisal guidance
    In development

  6. Orforglipron for managing overweight and obesity [ID6516]

    In development Reference number: GID-TA11650 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

    In development Reference number: GID-TA11643 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Ianalumab for treating active Sjogren's syndrome [ID6634]

    Awaiting development Reference number: GID-TA11836 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463]

    Awaiting development Reference number: GID-TA11590 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]

    Awaiting development Reference number: GID-TA11862 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Belzutifan with pembrolizumab for adjuvant treatment of clear cell renal cell carcinoma after nephrectomy [ID6645]

    Awaiting development Reference number: GID-TA11813 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Sotorasib with pemetrexed and carboplatin for untreated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6741]

    Awaiting development Reference number: GID-TA11967 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Remibrutinib for treating chronic inducible urticaria inadequately controlled by H1-antihistamines [ID6742]

    Awaiting development Reference number: GID-TA11968 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]

    In development Reference number: GID-TA11091 Expected publication date:  22 April 2026

    Technology appraisal guidance
    In development

  15. Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [ID1237]

    In development Reference number: GID-TA10239 Expected publication date:  06 August 2026

    Technology appraisal guidance
    In development